FDA Offers Guidance to Enhance Diversity in Clinical Trials

The FDA released a statement (9 November 2020) outlining its commitment to promoting greater diversity in medical product development and issuing a new guidance document outlining the agency’s thinking on encouraging greater inclusivity.

“Enhancing the Diversity of Clinical Trial Populations–Eligibility Criteria, Enrollment Practices, and Trial Designs.”

The guidance provides recommendations for sponsors on how to increase enrollment of underrepresented populations, guidance on broadening clinical trial eligibility criteria for clinical trials of investigational drugs intended to treat rare diseases and other considerations about the inclusion of important groups including racial and ethnic minorities, women and older people.

Read the full statement here.

Cromos Pharma proudly supports the Right2hope initiative, empowering patients to explore treatment options beyond traditional clinical trials. Through an intuitive, AI-supported matching algorithm, Right2hope connects patients with the most relevant expanded access, compassionate use, and right-to-try programs.